Jagsonpal Pharmaceuticals Ltd Q2FY26 PAT up at Rs. 12.57 crores

has reported Standalone financial results for the period ended September 30, 2025.

Financial Results (Q2 FY2026) - QoQ Comparison

The company has reported total income of Rs. 77.492 crores during the period ended September 30, 2025 as compared to Rs. 78.437 crores during the period ended June 30, 2025.

The company has posted net profit / (loss) of Rs. 12.574 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs. 10.795 crores for the period ended June 30, 2025.

The company has reported EPS of Rs. 1.87 for the period ended September 30, 2025 as compared to Rs. 1.58 for the period ended June 30, 2025.

Financials	Q2 FY2026	Q1 FY2026	% Change
Total Income	₹ 77.492 crs	₹78.437 crs	-1.20%
Net Profit	₹12.574 crs	₹10.795 crs	16.48%
EPS	₹ 1.87	₹1.58	18.35%

Financial Results (Q2 FY2026) - YoY Comparison

The company has reported total income of Rs. 77.492 crores during the period ended September 30, 2025 as compared to Rs.76.346 crores during the period ended September 30, 2024.

The company has posted net profit / (loss) of Rs.12.574 crores for the period ended September 30, 2025 as against net profit / (loss) of Rs.11.459 crores for the period ended September 30, 2024.

The company has reported EPS of Rs. 1.87 for the period ended September 30, 2025 as compared to Rs.1.70 for the period ended September 30, 2024.

Financials	Q2 FY2026	Q2 FY2025	% Change
Total Income	₹ 77.492 crs	₹76.346 crs	1.50%
Net Profit	₹12.574 crs	₹11.459 crs	9.73%
EPS	₹ 1.87	₹1.70	10.00%

Financial Results (Half Year Ended FY2026) - YoY Comparison

The company has reported total income of Rs.155.929 crores during the 6 Months period ended September 30, 2025 as compared to Rs.139.229 crores during the 6 Months period ended September 30, 2024.

The company has posted net profit / (loss) of Rs.23.369 crores for the 6 Months period ended September 30, 2025 as against net profit / (loss) of Rs.16.788 crores for the 6 Months period ended September 30, 2024.

The company has reported EPS of Rs.3.45 for the 6 Months period ended September 30, 2025 as compared to Rs.2.49 for the 6 Months period ended September 30, 2024.

Financials	Half Year Ended FY2026	Half Year Ended FY2025	% Change
Total Income	₹155.929 crs	₹139.229 crs	11.99%
Net Profit	₹23.369 crs	₹16.788 crs	39.20%
EPS	₹3.45	₹2.49	38.55%

Source : Equity Bulls

Keywords

JagsonpalPharmaceuticals Q2FY26 Q2FY2026 H1FY26 H1FY2026 ResultUpdate